Objective To investigate the clinical effect of anti- hepatitis B dendritic cell (HBV-DC) combined with thymosin α1 in the treatment of e antigen-negative chronic hepatitis B.Methods A total of 80 patients with e antigen-negative chronic hepatitis B were randomly divided into two groups, with 40 cases in each group. Control group received anti-HBV-DC for treatment, and experimental group received anti-HBV-DC combined with thymosin α1 for treatment. Curative effects of the two groups were compared.Results The experimental group had total effective rate as 95.0%, which was much higher than 85.0% of the control group, and their difference had statistical significance (P<0.05). The experimental group had lower levels of aspartate aminotransferase (AST) index and alanine aminotransferase (ALT) index than the control group, and their difference had statistical significance (P<0.05).Conclusion The morbidity of e antigen-negative chronic hepatitis B is high. Clinical treatment by anti-HBV-DC combined with thymosin α1 provides ideal effect in improving clinical effect and liver function. This method is worthy of promotion.%目的：探讨抗乙肝树突状细胞(HBV-DC)联合胸腺肽α1在e抗原阴性慢性乙型肝炎患者中的临床治疗效果。方法80例e抗原阴性慢性乙型肝炎患者，随机分为两组，每组40例。对照组采用抗HBV-DC治疗，实验组联合胸腺肽α1治疗，比较两组治疗效果。结果实验组总有效率95.0%，明显高于对照组85.0%，差异有统计学意义(P<0.05)；实验组谷草转氨酶(AST)指标、谷丙转氨酶(ALT)指标，低于对照组，差异有统计学意义(P<0.05)。结论e抗原阴性慢性乙型肝炎发病率较高，临床上采用抗HBV-DC联合胸腺肽α1治疗效果理想，能够提高临床疗效，改善患者肝功能，值得推广。
展开▼
